Famicord Ag

Name

Famicord Ag

Legal name

FamiCord AG

Website

https://famicord.com

Company type

Public

Founded year

2024

Operating status

Operating

Ownership category

akta.pro rank

Product category

Stem Cell Banking

NAICS

Blood and Organ Banks (621991), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Cell Therapy Manufacturing Services (GMP, autologous/allogeneic) (HLAAAKAC)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA) (HLAGAKAA)

Keywords

• Stem cell banking
• Cord blood storage
• Cell therapy manufacturing
• CDMO services
• Perinatal tissue preservation

Headquarters

HQ city

Leipzig

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales, Supply Chain

Revenue model

1. Family Stem Cell Banking Subscriptions: Ongoing subscription-based services for stem cell collection, processing, and long-term storage for families. Revenue generated through annual storage fees and initial processing fees.
2. CDMO Services for Biotech/Pharma: Contract manufacturing and development services for biotechnology companies and clinics, including process development, validation, cGMP manufacturing, and quality control for cell therapy products and ATMPs.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

FamiCord AG is the parent of the FamiCord Group, Europe's leading stem cell bank. Its core offerings are (1) family stem cell banking — collection, processing, testing, and long-term cryogenic storage of umbilical cord blood, cord tissue, and placenta tissue for expectant families — and (2) CDMO services for biotechnology companies and clinics, providing process development, tech transfer, cGMP manufacturing, analytics, cell/tissue sourcing, and global logistics for cell therapy ATMPs (Advanced Therapy Medicinal Products). The group operates cGMP-compliant manufacturing facilities in Warsaw (Poland), Cantanhede (Portugal), Leipzig (Germany), and Rostock (Germany), supporting autologous and allogeneic cell therapy programs from preclinical through clinical phases.

Product overview

FamiCord operates as a pan-European stem cell bank offering family banking services for umbilical cord blood and tissue preservation, alongside a CDMO (Contract Development and Manufacturing Organization) segment providing cell therapy development and manufacturing services to biotech companies and clinics. The company operates two cGMP-compliant manufacturing facilities in Warsaw (Poland) and Cantanhede (Portugal). Key offerings include Stem Cells Banking (family banking), CDMO Services, Compassionate Use Program/Expanded Access Programme for ASD and cerebral palsy treatments, and Stem Cell Applications for transplants. FamiCord is the first and leading European stem cell bank with over 1,000,000 stored cord blood units and partnerships with over 1,500 clinics across Europe.

Differentiator

Problem solved

Functional benefit

Brands

• VitaPlus: Stem cell banking contract variant offered by FamiCord
• VitaPlusCord

Products and services

• Stem Cells Banking Family banking service covering the collection, processing, testing, and long-term cryogenic storage of umbilical cord blood, umbilical cord tissue, and placenta tissue from newborns, intended to preserve perinatal cells for potential future medical treatments of the child or family members.
• CDMO Services for Cell Therapy ATMPs Contract Development and Manufacturing Organization services for biotech companies and clinics developing cell therapy Advanced Therapy Medicinal Products (ATMPs). Scope includes process development and optimization, technology transfer, cGMP manufacturing, cell and tissue sourcing, analytics, and global logistics, supporting autologous and allogeneic programs from preclinical through clinical phases.
• Compassionate Use Program / Expanded Access Programme Programme enabling families to access stem cell treatments for autism spectrum disorders and cerebral palsy using the child's own stored umbilical cord blood, leveraging FamiCord's position as the only private cord blood bank in Europe providing cells for innovative experimental therapies and clinical research.
• Stem Cell Applications (Transplants and Infusions) Therapeutic application services providing stem cell transplants and infusions to patients, using FamiCord-stored cord blood and tissue. The application portfolio has supported over 8,000 patients treated and over 260 cord blood transplantations or infusions enabled.

Quantifiable outcome

• Stored over 1,000,000 cord blood units and other biological materials
• +2 more outcomes

Named customers5 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• ArTheccoreStrategic or Co-development Partner · 23 June 2026ArThec is a new CDMO customer acquired by FamiCord AG in June 2026, representing further expansion in the CDMO business segment.
• US Biotechnology CompanycoreStrategic or Co-development PartnerAllogeneic cell therapy partnership for muscular dystrophy treatment. FamiCord provides technology transfer into the manufacturing process and cGMP production/QC release. Ongoing partnership since 2021.
• German Biotechnology CompanyminorStrategic or Co-development PartnerProcess development, validation, production and QC assessments for preclinical phase treatments of cartilage damage.
• Scandinavian Biotechnology CompanyminorStrategic or Co-development PartnerProcess development, production and quality control for Phase II clinical trial for diabetes treatment.
• Polish University CliniccoreStrategic or Co-development PartnerPartnership since 2017 for manufacturing and quality controls for autologous ATMPs for Phase I/II clinical studies for dermatological applications.
• 1,500+ Clinics across Europe, Asia and AfricacoreChannel Partner/ Reseller/ DistributorExtensive network of cooperating clinics that refer families and/or process samples through FamiCord facilities.
• Academic InstitutionsminorStrategic or Co-development PartnerPartnerships with academic institutions to contribute to advancements in regenerative medicine and biotechnology.

Scale indicators5 records

Recent moves1 record

Expansion highlights6 records

Broad incumbents

• Lonza Group: Global contract development and manufacturing organization (CDMO) with significant cell and gene therapy manufacturing capacity. Comparable as a much larger incumbent serving FamiCord's same biotech CDMO customers.
• Charles River Laboratories: Global CRO/CDMO providing cell and gene therapy manufacturing and testing services. Comparable as a broad incumbent offering overlapping capabilities in cell therapy process development and GMP release.
• Catalent: Major global CDMO with biologics and cell therapy capabilities. Comparable as a large incumbent competing for cell therapy ATMP process development, tech transfer and GMP manufacturing work that FamiCord's CDMO segment targets.

Emerging players

• BioLife Solutions: Supplier of cryopreservation and biopreservation tools for cell and gene therapies. Comparable as an enabler/adjacent player whose products are used in the same cold-chain and cryogenic storage workflows that FamiCord runs.
• Caladrius Biosciences (PCT Cell Therapy Services): Cell therapy CDMO with PCT heritage offering cGMP manufacturing services. Comparable as an emerging peer in cell therapy contract manufacturing, a smaller and more focused alternative to FamiCord's CDMO offering.

Direct peers

• Cells4Life: UK-based private cord blood bank offering whole-blood and tissue storage. Directly comparable on the family banking subscription model and is a relevant UK/European private-bank competitor.
• Cord Blood Registry (CBR): One of the largest private family cord blood banks in the US, owned by CooperSurgical. Directly comparable to FamiCord on core DTC cord blood collection, processing and long-term storage service.
• Cryo-Cell International: US-listed private cord blood banking company offering family cord blood and menstrual cell storage. Directly comparable to FamiCord's family banking subscription business and recurring storage revenue model.
• ViaCord (Revvity): Family cord blood and cord tissue banking service operating under Revvity/PerkinElmer. Directly comparable on family banking value proposition, scientific positioning and recurring storage model.

Regional players

• Crioestaminal: Portuguese private cord blood bank that is part of the FamiCord family (Cantanhede site). Relevant as a regional European private-bank peer operating under FamiCord's own platform and network.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/famicord-group
• Facebookfacebook.com/FamiCordGroup

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Famicord Ag